| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(09)61969-3 |
| P698 | PubMed publication ID | 20110121 |
| P2093 | author name string | Robert J Heine | |
| Craig J Currie | |||
| Marc Evans | |||
| Chris D Poole | |||
| John R Peters | |||
| Oswaldo L Bracco | |||
| Aodán Tynan | |||
| Tony Zagar | |||
| P2860 | cites work | Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes | Q22250887 |
| Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study | Q24652963 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| A new method of classifying prognostic comorbidity in longitudinal studies: development and validation | Q29547376 | ||
| Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes | Q29547541 | ||
| Effects of intensive glucose lowering in type 2 diabetes | Q29547736 | ||
| 10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 | ||
| Glucose control and vascular complications in veterans with type 2 diabetes | Q29619213 | ||
| Patients with type 2 diabetes undergoing coronary artery bypass graft surgery: predictors of outcomes. | Q33338746 | ||
| Validation of information recorded on general practitioner based computerised data resource in the United Kingdom | Q33539292 | ||
| Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. | Q33864120 | ||
| The influence of glucose-lowering therapies on cancer risk in type 2 diabetes | Q34609508 | ||
| Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials | Q34982751 | ||
| Intensive glucose control and macrovascular outcomes in type 2 diabetes. | Q34995674 | ||
| Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin | Q35771232 | ||
| A systematic review of the Charlson comorbidity index using Canadian administrative databases: a perspective on risk adjustment in critical care research | Q36193514 | ||
| Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors | Q36306246 | ||
| Glycemic control and prevention of microvascular and macrovascular disease in the Steno 2 study | Q36454866 | ||
| Biomarkers of atherosclerotic plaque instability and rupture | Q36643429 | ||
| Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors. | Q36945300 | ||
| Acute hyperglycemia and oxidative stress: direct cause and effect? | Q37069662 | ||
| Association between serious ischemic cardiac outcomes and medications used to treat diabetes | Q37082123 | ||
| Safety of very tight blood glucose control in type 2 diabetes | Q43063601 | ||
| Hypoglycemia in patients with type 2 diabetes mellitus | Q43659869 | ||
| Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin | Q46917157 | ||
| Hypokalaemia during insulin-induced hypoglycaemia in hypopituitary adults with and without growth hormone deficiency | Q48342775 | ||
| Mortality in people with Type 2 diabetes in the UK | Q61917095 | ||
| Diabetes and mortality following acute coronary syndromes | Q80796520 | ||
| P433 | issue | 9713 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 481-489 | |
| P577 | publication date | 2010-01-26 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study | |
| P478 | volume | 375 |
| Q42784640 | 6(th) Annual Symposium on Self-Monitoring of Blood Glucose (SMBG) applications and beyond, April 25-27, 2013, Riga, Latvia |
| Q90428563 | A 7.0-7.7% value for glycated haemoglobin is better than a <7% value as an appropriate target for patient-centered drug treatment of type 2 diabetes mellitus |
| Q90341385 | A Randomized Pilot Study of the Effect of Trelagliptin and Alogliptin on Glycemic Variability in Patients with Type 2 Diabetes |
| Q90528357 | A Randomized Trial of Alerting to Low Glycated Hemoglobin Level in Older Adults: Results of the Low Indexes of Metabolism Intervention Trial B (LIMIT-B) |
| Q47230597 | A network meta-analysis on the comparative efficacy of different dietary approaches on glycaemic control in patients with type 2 diabetes mellitus |
| Q34421981 | A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study |
| Q84175682 | ADVANCE and glycaemia thresholds: a need to clarify the statistical approach |
| Q35179853 | Achieved levels of HbA1c and likelihood of hospital admission in people with type 1 diabetes in the Scottish population: a study from the Scottish Diabetes Research Network Epidemiology Group |
| Q92550108 | Achievement of Target A1C <7.0% (<53 mmol/mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical Practice |
| Q28275281 | Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis |
| Q64086180 | Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus |
| Q28544402 | All-cause mortality in patients with type 2 diabetes in association with achieved hemoglobin A(1c), systolic blood pressure, and low-density lipoprotein cholesterol levels |
| Q34237363 | All-cause mortality risk among a national sample of individuals with diabetes |
| Q37516975 | Analysis of factors predicting mortality of new patients commencing renal replacement therapy 10 years of follow-up |
| Q35183113 | Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients--an analysis of the DiaRegis registry |
| Q36541839 | Are diabetes management guidelines applicable in 'real life'? |
| Q47986455 | Are psychopathological features relevant predictors of glucose control in patients with type 2 diabetes? A prospective study |
| Q38182542 | Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population? |
| Q47568907 | Are we missing hypoglycaemia? Elderly patients with insulin-treated diabetes present to primary care frequently with non-specific symptoms associated with hypoglycaemia. |
| Q97072589 | Association Between HbA1c Levels and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Cardiovascular Disease: A Secondary Analysis of the TECOS Randomized Clinical Trial |
| Q92811882 | Association between On-Treatment Haemoglobin A1c and All-Cause Mortality in Individuals with Type 2 Diabetes: Importance of Personalized Goals and Type of Anti-Hyperglycaemic Treatment |
| Q46773983 | Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study |
| Q35559292 | Association between hemoglobin A1c and carotid atherosclerosis in rural community-dwelling elderly Japanese men. |
| Q36629664 | Association between urinary markers of nucleic acid oxidation and mortality in type 2 diabetes: a population-based cohort study. |
| Q64241793 | Association of Diabetes Mellitus Status and Glycemic Control With Secondary Prevention Medication Adherence After Acute Myocardial Infarction |
| Q57312405 | Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds |
| Q64079773 | Association of Low Fasting Glucose and HbA1c With Cardiovascular Disease and Mortality: The MESA Study |
| Q51734353 | Association of Single Nucleotide Polymorphisms in CACNA 1A/CACNA 1C/CACNA 1H Calcium channel genes with Diabetic Peripheral Neuropathy in Chinese Population. |
| Q37193623 | Association of glycation gap with mortality and vascular complications in diabetes. |
| Q31013668 | Association of the average rate of change in HbA1c with severe adverse events: a longitudinal evaluation of audit data from the Bavarian Disease Management Program for patients with type 2 diabetes mellitus. |
| Q36845781 | Associations of HbA1c and educational level with risk of cardiovascular events in 32,871 drug-treated patients with Type 2 diabetes: a cohort study in primary care |
| Q93499735 | Authors' response |
| Q90571302 | BARI 2D: A Reanalysis Focusing on Cardiovascular Events |
| Q38073629 | Beneficial and detrimental effects of glycemic control on cardiovascular disease in type 2 diabetes |
| Q35197212 | Both high and low HbA1c predict incident heart failure in type 2 diabetes mellitus |
| Q88355882 | Burden of high blood pressure as a contributing factor to stroke in the Japanese community-based diabetic population |
| Q35857134 | Can Fasting Glucose Levels or Post-Breakfast Glucose Fluctuations Predict the Occurrence of Nocturnal Asymptomatic Hypoglycemia in Type 1 Diabetic Patients Receiving Basal-Bolus Insulin Therapy with Long-Acting Insulin? |
| Q57299792 | Cardiovascular Autonomic Neuropathy Predicts Higher HbA1c Variability in Subjects with Type 2 Diabetes Mellitus |
| Q51736764 | Cardiovascular Mortality of Oral Antidiabetic Drugs Approved Before and After the 2008 US FDA Guidance for Industry: A Systemic Review and Meta-Analysis. |
| Q42398936 | Cardiovascular disease and glycemic treatment |
| Q37202122 | Cardiovascular outcomes in framingham participants with diabetes: the importance of blood pressure. |
| Q45895265 | Cardiovascular safety of insulin: Between real-world data and reality |
| Q64122759 | Cause-specific risk of major adverse cardiovascular outcomes and hypoglycemic in patients with type 2 diabetes: a multicenter prospective cohort study |
| Q91942084 | Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes mellitus |
| Q47246352 | Changes in Antidiabetic Drug Prescription and Glycemic Control Trends in Elderly Patients with Type 2 Diabetes Mellitus from 2005-2013: An Analysis of the National Center Diabetes Database (NCDD-03). |
| Q36859777 | Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis |
| Q48799668 | Choosing targets for glycaemia, blood pressure and low-density lipoprotein cholesterol in elderly individuals with diabetes mellitus |
| Q38711884 | Choosing wisely in case of hypertension, diabetes and hyperlipidemia in older patients |
| Q34707612 | Clinical experience with insulin detemir: results from the Indonesian cohort of the international A₁chieve study |
| Q38107347 | Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence? |
| Q42219350 | Comment on 'New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer'. |
| Q48119986 | Comorbidity of chronic kidney disease, diabetes and lower glycated hemoglobin predicts support/care-need certification in community-dwelling older adults |
| Q43548151 | Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial |
| Q36103732 | Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. |
| Q38858785 | Comparison of morning basal + 1 bolus insulin therapy (insulin glulisine + insulin glargine 300 U/mL vs insulin lispro + insulin glargine biosimilar) using continuous glucose monitoring: A randomized crossover study. |
| Q51702145 | Consensus guidelines, algorithms and care of the individual patient with type 2 diabetes. |
| Q36335124 | Continuous Glucose Monitoring Systems: A Review |
| Q50046525 | Control of glycemia and blood pressure in British adults with diabetes mellitus and subsequent therapy choices: a comparison across health states. |
| Q36355228 | Coronary artery disease and diabetes mellitus |
| Q87887062 | Coronary artery disease severity modifies associations between glycemic control and both mortality and myocardial infarction |
| Q34620581 | Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics |
| Q45714250 | Daily glycaemic variability: benefits of optimal control |
| Q47871792 | Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years |
| Q36297059 | Death during intensive glycemic therapy of diabetes: mechanisms and implications |
| Q36959940 | DiaSurg 2 trial--surgical vs. medical treatment of insulin-dependent type 2 diabetes mellitus in patients with a body mass index between 26 and 35 kg/m2: study protocol of a randomized controlled multicenter trial--DRKS00004550. |
| Q64242008 | Diabetes Mellitus-Related All-Cause and Cardiovascular Mortality in a National Cohort of Adults |
| Q55049143 | Diabetes alone should not be a reason for withholding adjuvant chemotherapy for stage III colon cancer. |
| Q34141194 | Diabetes and dementia |
| Q38848512 | Diabetes control: Incidence of acute myocardial infarction and all-cause mortality among patients with 3-6 years' disease duration |
| Q99569228 | Diabetes in ageing: pathways for developing the evidence base for clinical guidance |
| Q30528669 | Diabetes in older adults |
| Q34308751 | Diabetes in older adults: a consensus report |
| Q38281522 | Diabetes in older people: new insights and remaining challenges. |
| Q44446658 | Diabetes: Hypoglycaemia, emergency care and diabetes mellitus |
| Q43999262 | Diabetes: Low HbA1c levels and mortality in type 2 diabetes mellitus |
| Q34829290 | Diabetes: glycaemic control in type 2 (drug treatments). |
| Q83396576 | Diabetes: glycemic control and outcomes in people with diabetes and CKD |
| Q33583012 | Diabetic Kidney Disease: A Syndrome Rather Than a Single Disease |
| Q43039163 | Diabetic maculopathy and retinopathy. Functional and sociomedical significance |
| Q46004736 | Diabète de type 2 et valeurs visées d’hémoglobine A1c. |
| Q42818456 | Diagnosis and management of type 2 diabetes |
| Q34116264 | Diet control to achieve euglycemia induces significant loss of heart and liver weight via increased autophagy compared with ad libitum diet in diabetic rats |
| Q38805174 | Differentiating clinical care from disease prevention: a prerequisite for practicing quaternary prevention |
| Q37893108 | Diversity in diabetes: the role of insulin aspart |
| Q37577159 | Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. |
| Q50554714 | Effect modification in the association between glycated haemoglobin and cardiovascular disease and mortality in patients with type 2 diabetes. |
| Q90371943 | Effect of induced hypoglycemia on inflammation and oxidative stress in type 2 diabetes and control subjects |
| Q24628988 | Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials |
| Q34026431 | Effect of telehealth on glycaemic control: analysis of patients with type 2 diabetes in the Whole Systems Demonstrator cluster randomised trial |
| Q36103818 | Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register |
| Q37145172 | Effectiveness of sulphonylureas in the therapy of diabetes mellitus type 2 patients: an observational cohort study |
| Q27009397 | Effects of monounsaturated fatty acids on glycaemic control in patients with abnormal glucose metabolism: a systematic review and meta-analysis |
| Q33804767 | Efficacy and safety of a lercanidipine/enalapril fixed-dose combination in hypertensive patients in Portugal |
| Q42694248 | Efficacy and safety of insulin glargine compared to other interventions in younger and older adults: a pooled analysis of nine open-label, randomized controlled trials in patients with type 2 diabetes |
| Q34448679 | Elimination of hypoglycemia from the lives of people affected by diabetes |
| Q46142568 | Establishing an evidence base for frequency of monitoring glycated haemoglobin levels in patients with Type 2 diabetes: projections of effectiveness from a regression model |
| Q40287198 | Euglycemia in Diabetic Rats Leads to Reduced Liver Weight via Increased Autophagy and Apoptosis through Increased AMPK and Caspase-3 and Decreased mTOR Activities |
| Q37969988 | European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary |
| Q60920025 | Evaluation of medication adherence among Lebanese diabetic patients |
| Q35322859 | Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin |
| Q48783771 | Exenatide in type 2 diabetes |
| Q58393403 | Exenatide may improve maintenance of HbA1c targets, with less hypoglycaemia, but more early adverse effects when compared with low-dose glimepiride |
| Q47727795 | Factors associated with stroke, myocardial infarction, ischemic heart disease, unstable angina, or mortality in patients from real world clinical practice with newly-diagnosed type 2 diabetes and early glycemic control |
| Q42858225 | General practice at the cutting edge of information technology, or failing to keep pace? |
| Q38262676 | Glucokinase MODY and implications for treatment goals of common forms of diabetes |
| Q39954906 | Glucose Levels and Risk of Frailty |
| Q36195926 | Glucose control and cardiovascular outcomes: reorienting approach |
| Q41685405 | Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study |
| Q53081527 | Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer. |
| Q31107244 | Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease - cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort |
| Q90355905 | Glycaemic control and excess risk of major coronary events in patients with type 2 diabetes: a population-based study |
| Q44647243 | Glycaemic control and the risk of mortality in elderly type 2 diabetic patients (ZODIAC-20). |
| Q90242341 | Glycaemic variation is a predictor of all-cause mortality in the Veteran Affairs Diabetes Trial |
| Q35682211 | Glycated Hemoglobin Level and Mortality in a Nondiabetic Population with CKD. |
| Q42261989 | Glycated Hemoglobin and All-Cause Mortality in Korean Type 2 Diabetes |
| Q64126995 | Glycated Hemoglobin and All-cause and Cause-specific Mortality Among Adults With and Without Diabetes |
| Q36512204 | Glycated Hemoglobin and Outcomes in Patients with Advanced Diabetic Chronic Kidney Disease |
| Q53578997 | Glycated hemoglobin and long-term prognosis in patients with suspected stable angina pectoris without diabetes mellitus: a prospective cohort study. |
| Q42028224 | Glycated lysine-141 in haptoglobin improves the diagnostic accuracy for type 2 diabetes mellitus in combination with glycated hemoglobin HbA1c and fasting plasma glucose |
| Q42851570 | Glycemia and cardiovascular diseases in type 2 diabetes |
| Q35748936 | Glycemic Control and Mortality in Diabetic Patients Undergoing Dialysis Focusing on the Effects of Age and Dialysis Type: A Prospective Cohort Study in Korea |
| Q42598787 | Glycemic Control in Older Adults With Diabetes Mellitus |
| Q53511750 | Glycemic control and disability-free survival in hypoglycemic agent-treated community-dwelling older patients with type 2 diabetes mellitus. |
| Q90091347 | Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years |
| Q35043215 | Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study |
| Q34486820 | Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease? |
| Q26860467 | Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis |
| Q84680379 | Goals for HbA1c Need To Be Individualized Based on Clinical Judgment, Instead of Third Party Recommendations |
| Q88154096 | Good glycaemic control is associated with a better prognosis in breast cancer patients with type 2 diabetes mellitus |
| Q37577111 | Guideline approach to therapy in patients with newly diagnosed type 2 diabetes |
| Q34252878 | Haemoglobin A1c even within non-diabetic level is a predictor of cardiovascular disease in a general Japanese population: the Hisayama Study |
| Q44501241 | HbA1c 3 months after diagnosis predicts premature mortality in patients with new onset type 2 diabetes |
| Q36307638 | HbA1c and all-cause mortality risk among patients with type 2 diabetes. |
| Q64943068 | HbA1c and hypoglycaemia in intensively treated type 2 diabetes: a retrospective cohort study in primary care. |
| Q37278073 | HbA1c and the risks for all-cause and cardiovascular mortality in the general Japanese population: NIPPON DATA90 |
| Q28728521 | HbA1c measured in stored erythrocytes is positively linearly associated with mortality in individuals with diabetes mellitus |
| Q39160789 | HbA1c: The lower the better? |
| Q38949358 | Hemoglobin A1c and Mortality in Older Adults With and Without Diabetes: Results From the National Health and Nutrition Examination Surveys (1988-2011). |
| Q36153786 | Hemoglobin a1c levels and the risk of cardiovascular disease in people without known diabetes: a population-based cohort study in Japan |
| Q36868093 | High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam Study |
| Q36533036 | High hemoglobin A1c levels within the non-diabetic range are associated with the risk of all cancers |
| Q44818709 | High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: a population-based study |
| Q33698584 | Hospital admissions for asthma, diabetes and COPD: is there an association with practice nurse staffing? A cross sectional study using routinely collected data |
| Q38137388 | How can we monitor glycaemic variability in the clinical setting? |
| Q38050151 | Humalog (lispro) for type 2 diabetes |
| Q91908825 | Hyperglycemia in non-obese patients with type 2 diabetes is associated with low muscle mass: The Multicenter Study for Clarifying Evidence for Sarcopenia in Patients with Diabetes Mellitus |
| Q46220548 | Hypoglycaemia is more frequent in type 2 diabetic patients with co-morbid vascular disease: an analysis of the DiaRegis registry |
| Q92705168 | Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management |
| Q35071447 | Hypoglycaemic events in patients with type 2 diabetes in the United Kingdom: associations with patient-reported outcomes and self-reported HbA1c |
| Q36783714 | Hypoglycemia and cardiovascular risks |
| Q36843938 | Hypoglycemia and glycemic variability are associated with mortality in non-intensive care unit hospitalized infectious disease patients with diabetes mellitus |
| Q34099164 | Hypoglycemia assessed by continuous glucose monitoring is associated with preclinical atherosclerosis in individuals with impaired glucose tolerance |
| Q35195244 | Hypoglycemia in older people - a less well recognized risk factor for frailty |
| Q47905607 | IAPT and Long Term Medical Conditions: What Can We Offer? |
| Q34609296 | Identification of undiagnosed diabetes and quality of diabetes care in the United States: cross-sectional study of 11.5 million primary care electronic records |
| Q92090975 | Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy |
| Q39844602 | Impact of cancer diagnosis and treatment on glycaemic control among individuals with colorectal cancer using glucose-lowering drugs |
| Q60486693 | Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia |
| Q47627556 | Impact of differing glucose-lowering regimens on the pattern of association between glucose control and survival. |
| Q38524435 | Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes |
| Q35898351 | Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes |
| Q33573537 | Impact of symptomatic hypoglycemia on medication adherence, patient satisfaction with treatment, and glycemic control in patients with type 2 diabetes |
| Q36783681 | Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs |
| Q39418202 | Impact of the use of anti-diabetic drugs on survival of diabetic dialysis patients: a 5-year retrospective cohort study in Taiwan |
| Q35667116 | Importance of Beta Cell Function for the Treatment of Type 2 Diabetes |
| Q37972353 | Improving diabetes management with electronic medical records |
| Q42389766 | In pursuit of normoglycaemia: the overtreatment of type 2 diabetes in general practice |
| Q64912869 | Incidence of cardiovascular disease and its associated risk factors in at-risk men and women in the United Arab Emirates: a 9-year retrospective cohort study. |
| Q35099790 | Increased coronary intervention rate among diabetic patients with poor glycaemic control: a cross-sectional study |
| Q89763476 | Increased risk of cardiovascular mortality by strict glycemic control (pre-procedural HbA1c < 6.5%) in Japanese medically-treated diabetic patients following percutaneous coronary intervention: a 10-year follow-up study |
| Q45342248 | Incretins and pancreatitis--what happens next? A personal viewpoint |
| Q36780304 | Independent contribution of A1C, systolic blood pressure, and LDL cholesterol control to risk of cardiovascular disease hospitalizations in type 2 diabetes: an observational cohort study |
| Q46792246 | Individualising treatment for older people with diabetes |
| Q36053616 | Inpatient HbA1c testing: a prospective observational study |
| Q34406780 | Inpatient costs for people with type 1 and type 2 diabetes in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group |
| Q28085428 | Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience |
| Q36926409 | Insulin Dose and Cardiovascular Mortality in the ACCORD Trial |
| Q33736297 | Insulin increases ceramide synthesis in skeletal muscle |
| Q26861313 | Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues |
| Q34417486 | Insulin therapy in critically ill patients |
| Q47280311 | Insulin use in elderly adults: risk of hypoglycemia and strategies for care |
| Q37636062 | Insulin-regulated protein palmitoylation impacts endothelial cell function. |
| Q36783839 | Insulin: potential negative consequences of early routine use in patients with type 2 diabetes |
| Q64067267 | Intensification to injectable therapy in type 2 diabetes: mixed methods study (protocol) |
| Q48751426 | Intensified glucose control in type 2 diabetes—whose agenda? |
| Q42945779 | Intensified glucose lowering in type 2 diabetes: time for a reappraisal |
| Q37784325 | Intensive Glucose Control and Cardiovascular Outcomes in Type 2 Diabetes |
| Q37173007 | Intra-cluster and inter-period correlation coefficients for cross-sectional cluster randomised controlled trials for type-2 diabetes in UK primary care |
| Q33894701 | Investigating the Relationship between Morning Glycemic Variability and Patient Characteristics Using Continuous Glucose Monitoring Data in Patients with Type 2 Diabetes |
| Q28258166 | Investigating the relationship between quality of primary care and premature mortality in England: a spatial whole-population study |
| Q36406150 | Investigation of the relationship between patient empowerment and glycaemic control in patients with type 2 diabetes: a cross-sectional analysis. |
| Q43717599 | Is glycemic control a quinidine-like intervention? |
| Q33880174 | Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis |
| Q85006371 | Large population data bases for primary care research: "We have the advantage" |
| Q38615171 | Lean diabetes in middle-aged adults: A joint analysis of the German DIVE and DPV registries. |
| Q34043195 | Level of A1C control and its predictors among Lebanese type 2 diabetic patients |
| Q91360138 | Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial |
| Q26799903 | Low HbA1c and Increased Mortality Risk-is Frailty a Confounding Factor? |
| Q47375082 | Low HbA1c and mortality: causation and confounding |
| Q36249585 | Low hemoglobin A(1c) in nondiabetic adults: an elevated risk state? |
| Q37414356 | Major Increases between Pre- and Post-breakfast Glucose Levels May Predict Nocturnal Hypoglycemia in Type 2 Diabetes |
| Q92956444 | Major adverse cardiovascular events in people with chronic kidney disease in relation to disease severity and diabetes status |
| Q30969902 | Making sense of the shadows: priorities for creating a learning healthcare system based on routinely collected data |
| Q33838353 | Management of diabetes and associated cardiovascular risk factors in seven countries: a comparison of data from national health examination surveys |
| Q38241645 | Management of diabetic nephropathy in older patients: a need for flexible guidelines |
| Q83320718 | Managing hyperglycaemia in patients with type 2 diabetes and known cardiovascular disease |
| Q35794228 | Material need insecurities, control of diabetes mellitus, and use of health care resources: results of the Measuring Economic Insecurity in Diabetes study. |
| Q53687296 | May the force be with you: why resistance training is essential for subjects with type 2 diabetes mellitus without complications. |
| Q88412797 | Mean HbA1c, HbA1c variability, and mortality in people with diabetes aged 70 years and older: a retrospective cohort study |
| Q35561210 | Mean glucose during ICU admission is related to mortality by a U-shaped curve in surgical and medical patients: a retrospective cohort study |
| Q33796751 | Measuring quality of life of old type 2 diabetic patients in primary care in Portugal: a cross-sectional study |
| Q37964744 | Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis |
| Q39952272 | Metabolic memory and all-cause death in community-based patients with type 2 diabetes: the Fremantle Diabetes Study. |
| Q35760316 | Metabolic memory and individual treatment aims in type 2 diabetes--outcome-lessons learned from large clinical trials |
| Q43607131 | Metformin and the risk of endometrial cancer: a population-based cohort study |
| Q38165601 | Metformin is associated with improved survival in endometrial cancer |
| Q38213039 | Mistakes, misunderstandings and controversies in diabetes: A review and personal account |
| Q58765755 | Mortality and cardiovascular disease burden of uncontrolled diabetes in a registry-based cohort: the ESCARVAL-risk study |
| Q36730207 | Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes |
| Q40704687 | Mortality in Individuals Aged 80 and Older with Type 2 Diabetes Mellitus in Relation to Glycosylated Hemoglobin, Blood Pressure, and Total Cholesterol. |
| Q46034115 | Myocyte membrane and microdomain modifications in diabetes: determinants of ischemic tolerance and cardioprotection. |
| Q42745263 | Neuropathy: the crystal ball for cardiovascular disease? |
| Q38519075 | New forms of insulin and insulin therapies for the treatment of type 2 diabetes |
| Q37277928 | New-onset diabetes in elderly subjects: association between HbA1c levels, mortality, and coronary revascularization |
| Q42501376 | Nigerian propolis improves blood glucose, glycated hemoglobin A1c, very low-density lipoprotein, and high-density lipoprotein levels in rat models of diabetes |
| Q35420896 | No association between hemoglobin A1c and in-hospital mortality in patients with diabetes and acute myocardial infarction |
| Q57202661 | No evidence of an increased mortality risk associated with low levels of glycated haemoglobin in a non-diabetic UK population |
| Q38378751 | Non-ICU hospital care of diabetes mellitus in the elderly population |
| Q58207412 | Non-high-density lipoprotein cholesterol: An important predictor of stroke and diabetes-related mortality in Japanese elderly diabetic patients |
| Q38841043 | Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile |
| Q38284244 | Optimal glycaemic control in elderly people with type 2 diabetes: what does the evidence say? |
| Q35976546 | Optimizing care in diabetes: a quixotic challenge |
| Q49072938 | Optimizing diabetes control in people with Type 2 diabetes through nurse-led telecoaching. |
| Q33617402 | PLA1A2 platelet polymorphism predicts mortality in prediabetic subjects of the population based KORA S4-Cohort |
| Q33576883 | PPBP and DEFA1/DEFA3 genes in hyperlipidaemia as feasible synergistic inflammatory biomarkers for coronary heart disease |
| Q92075830 | Paradoxical Relationship Between Glycated Hemoglobin and Longitudinal Change in Physical Functioning in Older Adults: A Prospective Cohort Study |
| Q84842031 | Parenchyma-sparing resections for pancreatic neuroendocrine tumors |
| Q59807619 | Patient clusters based on HbA1c trajectories: A step toward individualized medicine in type 2 diabetes |
| Q37973129 | Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes |
| Q35910471 | Physiological Changes in Older Adults and Their Effect on Diabetes Treatment |
| Q44281205 | Points for improvement: performance measurement for glycemic control in diabetes patients in a safety-net population |
| Q35225468 | Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study |
| Q41644888 | Prediction by Low Plasma HbA1c of Mortality, Cardiac and Noncardiac Disease Risk: Modulation by Diabetic Status and Sex. |
| Q48209843 | Predictive models for all-cause and cardiovascular mortality in type 2 diabetic inpatients. A cohort study |
| Q34433671 | Prevalence of and risk factors for diabetic macular edema in the United States |
| Q37370443 | Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational A1chieve study |
| Q48038695 | Profile of diabetes in men aged 79-97 years: the Western Australian Health in Men Study. |
| Q87851782 | Prognostic importance of baseline and serial glycated hemoglobin levels in high-risk patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study |
| Q47579878 | Protocol for the specialist supervised individualised multifactorial treatment of new clinically diagnosed type 2 diabetes in general practice (IDA): a prospective controlled multicentre open-label intervention study. |
| Q34060792 | Reasons given by general practitioners for non-treatment decisions in younger and older patients with newly diagnosed type 2 diabetes mellitus in the United Kingdom: a survey study |
| Q28534542 | Recent HbA1c values and mortality risk in type 2 diabetes. population-based case-control study |
| Q24605881 | Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization |
| Q34887952 | Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus |
| Q37898749 | Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing? |
| Q38047379 | Reducing cardiovascular disease risk in type 2 diabetes: is the focus on glycaemia warranted? |
| Q37394488 | Relationship Between Blood Pressure Values, Depressive Symptoms, and Cardiovascular Outcomes in Patients With Cardiometabolic Disease |
| Q43627828 | Relationship between HbA1c and risk of all-cause hospital admissions among people with Type 2 diabetes. |
| Q43729526 | Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes |
| Q92955029 | Relationship between glycated hemoglobin level and duration of hypoglycemia in type 2 diabetes patients treated with sulfonylureas: A multicenter cross-sectional study |
| Q35050565 | Relationship of HbA1c variability, absolute changes in HbA1c, and all-cause mortality in type 2 diabetes: a Danish population-based prospective observational study |
| Q41851925 | Resistance training for diabetes prevention and therapy: experimental findings and molecular mechanisms |
| Q46853716 | Retrospective analysis of 55,769 HbA1c EQA results obtained from professional laboratories and medical offices participating in surveys organized by two European EQA centers over a nine-year period |
| Q34738760 | Revisiting the J shaped curve, exploring the association between cardiovascular risk factors and concurrent depressive symptoms in patients with cardiometabolic disease: Findings from a large cross-sectional study |
| Q98725952 | Risk factors for retinopathy in hemodialysis patients with type 2 diabetes mellitus |
| Q34707600 | Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study |
| Q89976633 | Salvianolic Acid A Ameliorates Early-Stage Atherosclerosis Development by Inhibiting NLRP3 Inflammasome Activation in Zucker Diabetic Fatty Rats |
| Q34421536 | Serial Glycosylated Hemoglobin Levels and Risk of Colorectal Neoplasia among Patients with Type 2 Diabetes Mellitus |
| Q36047275 | Severe hypoglycemia and cardiovascular disease incidence in type 1 diabetes: the EURODIAB Prospective Complications Study |
| Q45068001 | Severe hypoglycemia and coronary artery calcification during the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. |
| Q43018895 | Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients |
| Q43883183 | Short-term impact of HbA1c on morbidity and all-cause mortality in people with type 2 diabetes: a Danish population-based observational study |
| Q57065992 | Sobrediagnóstico y sobretratamiento en el ámbito cardiovascular: factores de riesgo, no enfermedades |
| Q37858366 | Special considerations for the use of insulin in older adults |
| Q34541875 | Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus. |
| Q58053312 | Study of Once Daily Levemir (SOLVE™): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice |
| Q44173270 | Surgical outcomes of total knee replacement according to diabetes status and glycemic control, 2001 to 2009. |
| Q84107087 | Survival as a function of HbA(1c) in people with type 2 diabetes |
| Q94998469 | Survival as a function of HbA(1c) in people with type 2 diabetes |
| Q94998470 | Survival as a function of HbA(1c) in people with type 2 diabetes |
| Q44792169 | Survival as a function of HbA(1c) in people with type 2 diabetes. |
| Q42906377 | Tailoring treatment to risk in type 2 diabetes |
| Q37885149 | Taking hypoglycaemia seriously: diabetes, dementia and heart disease |
| Q38092138 | Taking small steps towards targets - perspectives for clinical practice in diabetes, cardiometabolic disorders and beyond. |
| Q35558180 | Target values of cardiovascular risk factors are not associated with all-cause mortality in patients with type 2 diabetes mellitus |
| Q24186667 | Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus |
| Q24202505 | Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus |
| Q24236456 | Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus |
| Q35025208 | The HbA1c and all-cause mortality relationship in patients with type 2 diabetes is J-shaped: a meta-analysis of observational studies |
| Q99238076 | The Impact of Physical Activity on Glycemic Variability Assessed by Continuous Glucose Monitoring in Patients With Type 2 Diabetes Mellitus: A Systematic Review |
| Q36467465 | The U-shaped Relationship of Traditional Cardiovascular Risk Factors and Adverse Outcomes in Later Life |
| Q37403177 | The association between different A1C-based measures of glycemia and risk of cardiovascular disease hospitalization |
| Q33869676 | The association between the baseline bone resorption marker CTX and incident dysglycemia after 4 years |
| Q91841579 | The association of glycated hemoglobin with mortality and ESKD among persons with diabetes and chronic kidney disease |
| Q64236215 | The association of intravenous insulin and glucose infusion with intensive care unit and hospital mortality: a retrospective study |
| Q55024341 | The association study of high-sensitivity C-reactive protein, pentraxin 3, nitrotyrosine, and insulin dose in patients with insulin-treated type 2 diabetes mellitus. |
| Q64228177 | The benefits of non-surgical weight management on weight and glycaemic control in people with complex type 2 diabetes: A primary care service evaluation of clinical outcomes at 12 months |
| Q37734903 | The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence |
| Q36222900 | The changing face of chronic illness management in primary care: a qualitative study of underlying influences and unintended outcomes |
| Q38793748 | The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial |
| Q37474232 | The effect of frailty should be considered in the management plan of older people with Type 2 diabetes |
| Q38885733 | The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study |
| Q30393989 | The glucose triad and its role in comprehensive glycaemic control: current status, future management |
| Q37895979 | The growing role of bariatric surgery in the management of type 2 diabetes: evidences and open questions. |
| Q35073167 | The impact of a diabetes local enhanced service on quality outcome framework diabetes outcomes |
| Q35391563 | The impact of diabetes mellitus and corresponding HbA1c levels on the future risks of cardiovascular disease and mortality: a representative cohort study in Taiwan |
| Q43709649 | The impact of metabolic control and QTc prolongation on all-cause mortality in patients with type 2 diabetes and foot ulcers |
| Q47208583 | The low indexes of metabolism intervention trial (LIMIT): design and baseline data of a randomized controlled clinical trial to evaluate how alerting primary care teams to low metabolic values, could affect the health of patients aged 75 or older |
| Q38161347 | The proarrhythmic effect of hypoglycemia: evidence for increased risk from ischemia and bradycardia |
| Q84806554 | The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes |
| Q35104031 | The role of bile acid sequestrants in the management of type 2 diabetes mellitus |
| Q37898750 | The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern |
| Q88721836 | The somatostatin-secreting pancreatic δ-cell in health and disease |
| Q37634244 | The treatment of type 2 diabetes |
| Q26995176 | Treating the elderly diabetic patient: special considerations |
| Q35128612 | Treatment-dependent and treatment-independent risk factors associated with the risk of diabetes-related events: a retrospective analysis based on 229,042 patients with type 2 diabetes mellitus |
| Q42907013 | Type 2 diabetes and hemoglobin A1c targets |
| Q34620430 | Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies |
| Q37837496 | Type 2 diabetes mellitus--current therapies and the emergence of surgical options |
| Q36370258 | Type 2 diabetes: a cohort study of treatment, ethnic and social group influences on glycated haemoglobin |
| Q38213328 | Type-2 diabetes and coronary heart disease: common physiopathology, viewed from autoimmunity |
| Q30651159 | UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. |
| Q92684923 | Updated Geriatric Cardiology Guidelines of the Brazilian Society of Cardiology - 2019 |
| Q94665718 | Use of Glycated Hemoglobin (A1c) as a Biomarker for Vascular Risk in Type 2 Diabetes: Its Relationship with Matrix Metalloproteinases-2, -9 and the Metabolism of Collagen IV and Elastin |
| Q36159023 | Use of an Electronic Medical Record (EMR) to Identify Glycemic Intensification Strategies in Type 2 Diabetes |
| Q46598580 | Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs. |
| Q38137389 | What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus? |
| Q42786169 | What has changed in the therapeutic strategy for type 2 diabetes mellitus? |
| Q85524170 | [Current treatment of type 2 diabetes] |
| Q84373566 | [Diabetes and cardiovascular diseases in old age] |
| Q87698329 | [Diabetes care and incidence of severe hypoglycemia in nursing home facilities and nursing services: The Heidelberg Diabetes Study] |
| Q83476573 | [Diabetes in the elderly] |
| Q83672379 | [New differential therapy of type 2 diabetes] |
| Q88027197 | [Treatment of type 2 diabetes in elderly patients] |
Search more.